Publications by authors named "T Synold"
Article Synopsis
- Eribulin is a microtubule dynamics inhibitor that shows potential for managing brain tumors, especially breast cancer brain metastases, due to its lower protein binding and resistance to P-glycoprotein extrusion.
- A clinical study involved administering eribulin to cancer patients post-tumor removal, with samples analyzed to measure its concentrations in the brain and plasma.
- Results indicated higher concentrations of eribulin in areas where the blood-brain barrier was disrupted, but overall levels in the brain were not enough to confirm consistent clinical effectiveness against brain tumors.
Background: In a previously reported Phase I trial, we observed therapy-associated declines in circulating myeloid-derived suppressor cells (MDSCs) with the administration of white button mushroom (WBM) tablets in prostate cancer (PCa) patients. These observations led us to hypothesise that WBM could mitigate PCa progression by suppressing MDSCs.
Methods: We performed bidirectional translational research to examine the immunomodulatory effects of WBM consumption in both syngeneic murine PCa models and patients with PCa participating in an ongoing randomised Phase II trial (NCT04519879).
The DNA-dependent protein kinase (DNA-PK) is an abundant nuclear protein that mediates DNA double-strand break repair by nonhomologous end joining (NHEJ). As such, DNA-PK is critical for V(D)J recombination in lymphocytes and for survival in cells exposed to ionizing radiation and clastogens. Peposertib (M3814) is a small molecule DNA-PK inhibitor currently in preclinical and clinical development for cancer treatment.
View Article and Find Full Text PDFArticle Synopsis
- The EVEREST trial investigated the effectiveness of adjuvant everolimus in patients with intermediate-high to very high risk of recurrence after kidney cancer surgery, showing a significant improvement in recurrence-free survival (RFS) but not in overall survival (OS).
- Of the 699 patients analyzed with very high-risk clear cell histology, those taking everolimus experienced a notable increase in RFS (HR 0.80) compared to placebo, although a high percentage (47%) of patients on everolimus discontinued treatment due to side effects.
- While everolimus improved RFS, the lack of statistically significant OS benefits suggests that further examination is needed to assess its long-term survival impact
To support a phase 1 trial in patients with lymphomas, we developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for tazemetostat quantitation in 20 μL of human plasma. After protein precipitation, chromatographic separation employed a Kinetex C18 column and a gradient of 0.1% formic acid in both water and acetonitrile, during a 3-min run time.
View Article and Find Full Text PDF